CRISPR Therapeutics AG (CRSP)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Chairman | 1.35M | 4.06M | 1978 |
| Dr. Raju Yashaswi Prasad Ph.D. | Chief Financial Officer | 880.1k | -- | 1984 |
| Mr. James R. Kasinger | General Counsel & Secretary | 734.72k | -- | 1972 |
| Mr. Shaun Foy | Founder | -- | -- | -- |
| Dr. Emmanuelle Marie Charpentier | Co-Founder & Scientific Advisory Board Member | -- | -- | -- |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | -- | -- | -- |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder | -- | -- | -- |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | -- | -- | 1966 |
| Dr. Daniel G. Anderson Ph.D. | Scientific Founder & Advisory Board Member | -- | -- | -- |
| Mr. Stephen Kennedy | Head of Technical Operations | -- | -- | -- |
CRISPR Therapeutics AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 407
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Corporate Governance
Recent Events
- Apr 09, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 27, 2024PRE 14A: Proxy StatementsSee Full Filing
- Feb 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 13, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing